| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Cardiothoracic Surgery, Emory University, Atlanta, Georgia, United States
2 Atlanta, Georgia, United States; Cardiothoracic Surgery, Emory University, Atlanta, Georgia, United States
3 Cardiothoracic Research laboratory, Emory University, Altanta, Georgia, United States; Applied Cardiovascular Research, Baker Heart Research institute, PO Box 6492, Melbourne, Victoria, 8008, Australia
4 Physiology and Pharmacology, James Cook University, Townsville, Queensland, Australia
* To whom correspondence should be addressed. E-mail: jvinten{at}emory.edu.
Reperfusion is the definitive treatment to salvage ischemic myocardium from infarction. A primary determinant of infarct size is the duration of ischemia. In myocardium that has not been irreversibly injured by ischemia, reperfusion induces additional injury in the area at risk. The heart has potent innate cardioprotective mechanisms against ischemia-reperfusion that reduce infarct size and other presentations of post-ischemic injury. Ischemic preconditioning (IPC) applied before the prolonged ischemia exerts the most potent protection observed among known strategies. It has been assumed that IPC exerts protection during ischemia. However, recent data suggest that cardioprotection is also exerted during reperfusion. Postconditioning (PoC), defined as brief intermittent cycles of ischemia alternating with reperfusion applied after the ischemic event, has been shown to reduce infarct size, in some cases equivalent to that observed with IPC. Although there are similarities in mechanisms of cardioprotection by these two interventions, there are key differences that go beyond simply exerting these mechanisms before or after ischemia. A significant limitation of IPC has been the inability to apply this maneuver clinically except in situations where the ischemic event can be predicted. On the other hand, PoC is applied at the point of service in the hospital [cath-lab for percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) and other cardiac surgery)] where and when reperfusion is initiated. Initial clinical studies are in agreement with the success and extent to which PoC reduces infarct size and myocardial injury, even in the presence of multiple co-morbidities.
This article has been cited by other articles:
|
|
 |
|
  L. Gomez, B. Li, N. Mewton, I. Sanchez, C. Piot, M. Elbaz, and M. Ovize Inhibition of mitochondrial permeability transition pore opening: translation to patients Cardiovasc Res, July 15, 2009; 83(2): 226 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Granfeldt, D. J. Lefer, and J. Vinten-Johansen Protective ischaemia in patients: preconditioning and postconditioning Cardiovasc Res, July 15, 2009; 83(2): 234 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hecht, J. Rong, A. L. F. Sampaio, C. Hermesh, C. Rutledge, R. Shemesh, A. Toporik, M. Beiman, L. Dassa, H. Niv, et al. A Novel Peptide Agonist of Formyl-Peptide Receptor-Like 1 (ALX) Displays Anti-Inflammatory and Cardioprotective Effects J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 426 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yang, J. Linden, S. S. Berr, I. L. Kron, G. A. Beller, and B. A. French Timing of adenosine 2A receptor stimulation relative to reperfusion has differential effects on infarct size and cardiac function as assessed in mice by MRI Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2328 - H2335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Thibault, C. Piot, P. Staat, L. Bontemps, C. Sportouch, G. Rioufol, T. T. Cung, E. Bonnefoy, D. Angoulvant, J.-F. Aupetit, et al. Long-Term Benefit of Postconditioning Circulation, February 26, 2008; 117(8): 1037 - 1044. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
